Mink Therapeutics Inc expected to post a loss of 50 cents a share - Earnings Preview

Mink Therapeutics

14/03/2025 13:11

Mink Therapeutics Inc INKT.OQ INKT.O is expected to show no change in quarterly revenue when it reports  results on March 18 for the period ending December 31 2024

​LSEG's mean analyst estimate for Mink Therapeutics Inc is for a loss of 50 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Mink Therapeutics Inc is $40.00​, above​ its last closing price of $7.98. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.80
-0.80
-0.50
Beat
37.5
Jun. 30 2024
-0.98
-1.00
-0.70
Beat
30
Mar. 31 2024
-1.58
-1.53
-1.10
Beat
28.3​
Dec. 31 2023
-1.53
-1.60
Missed
-4.3
​​Sep. 30 2023
-1.79
-1.82
-1.50
Beat
17.8
Jun. 30 2023
-1.91
-1.97
-1.80
Beat
8.9​
Mar. 31 2023
-2.49
-2.37
-1.70
Beat
28.4
Dec. 31 2022
-2.10
-2.30
Missed
-9.5

This summary was machine generated March 14 at 13:11 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)